<br>        Inclusion Criteria:<br><br>          -  Female subjects 18 years of age or older with FIGO Stages III-IV epithelial ovarian,<br>             primary peritoneal or fallopian tube cancer with an indication for first-line<br>             treatment with paclitaxel and carboplatin x 6 cycles (Subjects with pseudomyxoma,<br>             mesothelioma, adenocarcinoma with an unknown primary tumour, carcinosarcoma, sarcoma,<br>             mucinous or neuroendocrine histology are excluded<br><br>          -  Subjects with FIGO Stage IIIA or IIIB disease must have undergone PDS for ovarian,<br>             primary peritoneal or fallopian tube cancer within 12 weeks prior to randomization<br><br>          -  Subjects with FIGO Stage IIIC or IV disease must either:<br><br>          -  Undergo PDS for epithelial ovarian, primary peritoneal or fallopian tube cancer within<br>             12 weeks prior to randomization or<br><br>          -  Plan to have IDS following 3 cycles of paclitaxel and carboplatin plus AMG 386 or AMG<br>             386 placebo for biopsy proven epithelial ovarian, primary peritoneal or fallopian tube<br>             cancer<br><br>          -  ECOG performance status of 0 or 1<br><br>          -  Adequate bone marrow, renal and hepatic function<br><br>        Exclusion Criteria:<br><br>          -  Prior use of any anticancer therapy or experimental therapy for epithelial ovarian,<br>             primary peritoneal or fallopian tube cancer<br><br>          -  Previous abdominal and/or pelvic external beam radiotherapy<br><br>          -  History of central nervous metastasis<br><br>          -  History of arterial or venous thromboembolism within 12 months prior to randomization<br><br>          -  Clinically significant cardiovascular disease within 12 months prior to randomization<br>      ;<br>        Inclusion Criteria:<br><br>          -  Female subjects 18 years of age or older with FIGO Stages III-IV epithelial ovarian,<br>             primary peritoneal or fallopian tube cancer with an indication for first-line<br>             treatment with paclitaxel and carboplatin x 6 cycles (Subjects with pseudomyxoma,<br>             mesothelioma, adenocarcinoma with an unknown primary tumour, carcinosarcoma, sarcoma,<br>             mucinous or neuroendocrine histology are excluded<br><br>          -  Subjects with FIGO Stage IIIA or IIIB disease must have undergone PDS for ovarian,<br>             primary peritoneal or fallopian tube cancer within 12 weeks prior to randomization<br><br>          -  Subjects with FIGO Stage IIIC or IV disease must either:<br><br>          -  Undergo PDS for epithelial ovarian, primary peritoneal or fallopian tube cancer within<br>             12 weeks prior to randomization or<br><br>          -  Plan to have IDS following 3 cycles of paclitaxel and carboplatin plus AMG 386 or AMG<br>             386 placebo for biopsy proven epithelial ovarian, primary peritoneal or fallopian tube<br>             cancer<br><br>          -  ECOG performance status of 0 or 1<br><br>          -  Adequate bone marrow, renal and hepatic function<br><br>        Exclusion Criteria:<br><br>          -  Prior use of any anticancer therapy or experimental therapy for epithelial ovarian,<br>             primary peritoneal or fallopian tube cancer<br><br>          -  Previous abdominal and/or pelvic external beam radiotherapy<br><br>          -  History of central nervous metastasis<br><br>          -  History of arterial or venous thromboembolism within 12 months prior to randomization<br><br>          -  Clinically significant cardiovascular disease within 12 months prior to randomization<br>      ;<br>        Inclusion Criteria:<br><br>          -  Female subjects 18 years of age or older with FIGO Stages III-IV epithelial ovarian,<br>             primary peritoneal or fallopian tube cancer with an indication for first-line<br>             treatment with paclitaxel and carboplatin x 6 cycles (Subjects with pseudomyxoma,<br>             mesothelioma, adenocarcinoma with an unknown primary tumour, carcinosarcoma, sarcoma,<br>             mucinous or neuroendocrine histology are excluded<br><br>          -  Subjects with FIGO Stage IIIA or IIIB disease must have undergone PDS for ovarian,<br>             primary peritoneal or fallopian tube cancer within 12 weeks prior to randomization<br><br>          -  Subjects with FIGO Stage IIIC or IV disease must either:<br><br>          -  Undergo PDS for epithelial ovarian, primary peritoneal or fallopian tube cancer within<br>             12 weeks prior to randomization or<br><br>          -  Plan to have IDS following 3 cycles of paclitaxel and carboplatin plus AMG 386 or AMG<br>             386 placebo for biopsy proven epithelial ovarian, primary peritoneal or fallopian tube<br>             cancer<br><br>          -  ECOG performance status of 0 or 1<br><br>          -  Adequate bone marrow, renal and hepatic function<br><br>        Exclusion Criteria:<br><br>          -  Prior use of any anticancer therapy or experimental therapy for epithelial ovarian,<br>             primary peritoneal or fallopian tube cancer<br><br>          -  Previous abdominal and/or pelvic external beam radiotherapy<br><br>          -  History of central nervous metastasis<br><br>          -  History of arterial or venous thromboembolism within 12 months prior to randomization<br><br>          -  Clinically significant cardiovascular disease within 12 months prior to randomization<br>      ;<br>        Inclusion Criteria:<br><br>          -  Female subjects 18 years of age or older with FIGO Stages III-IV epithelial ovarian,<br>             primary peritoneal or fallopian tube cancer with an indication for first-line<br>             treatment with paclitaxel and carboplatin x 6 cycles (Subjects with pseudomyxoma,<br>             mesothelioma, adenocarcinoma with an unknown primary tumour, carcinosarcoma, sarcoma,<br>             mucinous or neuroendocrine histology are excluded<br><br>          -  Subjects with FIGO Stage IIIA or IIIB disease must have undergone PDS for ovarian,<br>             primary peritoneal or fallopian tube cancer within 12 weeks prior to randomization<br><br>          -  Subjects with FIGO Stage IIIC or IV disease must either:<br><br>          -  Undergo PDS for epithelial ovarian, primary peritoneal or fallopian tube cancer within<br>             12 weeks prior to randomization or<br><br>          -  Plan to have IDS following 3 cycles of paclitaxel and carboplatin plus AMG 386 or AMG<br>             386 placebo for biopsy proven epithelial ovarian, primary peritoneal or fallopian tube<br>             cancer<br><br>          -  ECOG performance status of 0 or 1<br><br>          -  Adequate bone marrow, renal and hepatic function<br><br>        Exclusion Criteria:<br><br>          -  Prior use of any anticancer therapy or experimental therapy for epithelial ovarian,<br>             primary peritoneal or fallopian tube cancer<br><br>          -  Previous abdominal and/or pelvic external beam radiotherapy<br><br>          -  History of central nervous metastasis<br><br>          -  History of arterial or venous thromboembolism within 12 months prior to randomization<br><br>          -  Clinically significant cardiovascular disease within 12 months prior to randomization<br>